Document is current
Any future updates will be listed below
-
Authors
Carrasco Lorenzo, Antonio https://orcid.org/0009-0008-9805-6403
Lop Gros, Joan https://orcid.org/0000-0002-9442-5688
Castrejón, Natalia https://orcid.org/0000-0002-0647-3058
García-Herrera, Adriana https://orcid.org/0000-0002-9731-0982
Albero-González, Raquel https://orcid.org/0000-0001-9027-1426
Saco, Adela
Montironi, Carla https://orcid.org/0000-0002-1453-2193
Alonso, Paula https://orcid.org/0009-0007-9859-7819
Luzon, Irea https://orcid.org/0009-0009-4150-7741
López, Vanessa https://orcid.org/0009-0004-1017-1708
Rodríguez, Laura https://orcid.org/0009-0007-4740-3316
Carrera, Cristina https://orcid.org/0000-0003-1608-8820
Alòs, Llúcia https://orcid.org/0000-0002-3460-0384
Teixido, Cristina https://orcid.org/0000-0002-7226-6567
-
Funding
Funding for this research was provided by:
Fundació Institució dels Centres de Recerca de Catalunya
- License Information
-
More Information
Article History
Received: 21 February 2026
Revised: 10 March 2026
Accepted: 15 March 2026
First Online: 8 April 2026
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee for Research with Medicinal Products (CEIm) of Hospital Clínic de Barcelona (Reg. HCB/2025/0500; Act 9/2025, meeting held on 15 May 2025).
: Informed consent was waived by the CEIm/Institutional Review Board due to the retrospective nature of the study and the use of anonymised/pseudonymised data. No identifiable patient information is included in this article.
: C.T has received research support from Novartis and AstraZeneca and has received a speaker honorarium and/or advisory board fees from Roche Pharma, Lilly, AstraZeneca, MSD. The remaining authors declare no competing interests related to this study.
